Avedro Announces FDA Priority Review Status for Corneal Cross‐linking New Drug Application
If Approved, Avedro Could Be Entitled to Seven Years Market Exclusivity
Waltham, Massachusetts, USA, November 25, 2013
Avedro Inc., a Boston‐based ophthalmic medical device and pharmaceutical company announces that it received notification from the U.S. Food and Drug Administration (FDA) stating that their NDA for riboflavin ophthalmic solution/KXL system has been filed, and has been granted priority review status. The priority review status places the application action date (PDUFA) at March 15th, 2014. Read more.
Grand Junction, Colorado, January 12, 2012
Marty Dalsing, President of Contamac, US, announced the establishment of a new grant in support of the non-profit National Keratoconus Foundation. The grant, which will be ongoing, will be supporting the launch of Bausch + Lomb’s KeraSoftTM contact lenses for keratoconus. These lenses, recently licensed for release in North America, are manufactured exclusively in Contamac’s Definitive™ Silicone Hydrogel material.
“For every prescription KeraSoft lens prescribed in North America, Contamac will donate a portion of the Definitive material sales as an unrestricted grant to the National Keratoconus Foundation,” said Dalsing. Read more…[schema type=”book” url=”http://localhost/dcer_nkcf_rebuilt/press-releases/” name=”Press Releases” description=”The National Keratoconus Foundation is your source on press releases on Keratoconus.” author=”Catherine Warren” ]